Phase II study of weekly carboplatin in pretreated adult malignant gliomas

  • Veronica Villani
  • Andrea Pace
  • Antonello Vidiri
  • Antonio Tanzilli
  • Francesca Sperati
  • Irene Terrenato
  • Carosi Mariantonia
  • Beatrice Casini
  • Giulio Metro
  • Marta Maschio
  • Koudriavtseva Tatiana
  • Francesco Cognetti
  • Alessandra FabiEmail author
Clinical Study



Patients with relapse of recurrent glioma have a poor outcome and limited treatment options. The aim of this study is to investigate the clinical benefit and tolerability of weekly intravenous administration of carboplatin-based monotherapy in adult glioma patients who had progressed from previous chemotherapy lines based on temozolomide and nitrosoureas.


This was a single-arm, phase II study. Eligibility criteria included progressive or recurrent glioma after radiotherapy and chemotherapy-based treatments and Karnofsky performance status (KPS) > 60.


Thirty-two patients (median age 43.5 years) were enrolled to receive weekly carboplatin monotherapy in an intravenous method of administration. The median duration of response was 7.3 months with an overall disease control rate of 31.3%. Median progression-free survival was 2.3 months while overall survival was 5.5 months. Pre-treatment with corticosteroids (i.e. dexamethasone) was associated to clinical benefit in 43.8% of patients. Patients achieving clinical benefit exhibited a longer progression-free survival (4.6 vs. 1.5 months; p > 0.001) and overall survival (7.9 vs. 3.2 months; p = 0.041) compared with those not achieving clinical benefit.


Our findings show that single agent, weekly, intravenous administration of carboplatin may have a role in patients with recurrent glioma and suggest that pre-treatment with corticosteroids may confer survival benefit.


Glioblastoma Recurrence Carboplatin Progression-free survival Corticosteroid use 



Editorial assistance was provided by Luca Giacomelli, PhD, Chiara Degirolamo, PhD, and Aashni Shah, from Polistudium (Milan, Italy); this assistance was supported by internal funds.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human and/or animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Regina Elena Institute, Rome, Italy) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Lapointe S, Perry A, Butowski NA (2018) Primary brain tumours in adults. Lancet 392:432–446CrossRefGoogle Scholar
  2. 2.
    Crocetti E, Trama A, Stiller C et al (2012) Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 48(10):1532–1542CrossRefGoogle Scholar
  3. 3.
    Brandes AA, Finocchiaro G, Zagonel V et al (2016) AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro Oncol 18:1304–1312CrossRefGoogle Scholar
  4. 4.
    Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507CrossRefGoogle Scholar
  5. 5.
    Franceschi E, Lamberti G, Paccapelo A et al (2018) Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? J Neurooncol 139:383–388CrossRefGoogle Scholar
  6. 6.
    Prelaj A, Rebuzzi SE, Grassi M et al (2019) Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: survival across disease and treatment subgroup analysis and review of the literature. Mol Clin Oncol 10:58–66Google Scholar
  7. 7.
    Davis ME (2016) Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 20:S2–S8CrossRefGoogle Scholar
  8. 8.
    Mrugala MM, Crew LK, Fink JR, Spence AM (2012) Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett 4:1082–1086CrossRefGoogle Scholar
  9. 9.
    Yung WK, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9(5):860–864CrossRefGoogle Scholar
  10. 10.
    Warnick RE, Prados MD, Mack EE et al (1994) A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19(1):69–74CrossRefGoogle Scholar
  11. 11.
    Reardon DA, Desjardins A, Peters KB et al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 107(1):155–164CrossRefGoogle Scholar
  12. 12.
    Francesconi AB, Dupre S, Matos M et al (2010) Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 17(8):970–974CrossRefGoogle Scholar
  13. 13.
    Field KM, Simes J, Nowak AK et al (2015) Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 17:1504–1513CrossRefGoogle Scholar
  14. 14.
    Pignata S, Breda E, Scambia G et al (2008) A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 66:229–236CrossRefGoogle Scholar
  15. 15.
    Jatoi A, Stella PJ, Hillman S et al (2003) Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (≥ 65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol. 26:441–447CrossRefGoogle Scholar
  16. 16.
    Wesseling P, Capser D (2018) WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol 44:139–150CrossRefGoogle Scholar
  17. 17.
    Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756CrossRefGoogle Scholar
  18. 18.
    Wen PY, Macdonald DR, Reardon DA et al (2010) Updated Response Assessment Criteria for high grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefGoogle Scholar
  19. 19.
    Prelaj A, Rebuzzi SE, Grassi M et al (2019) Multimodal treatment for local recurrent malignant gliomas: re-surgery and/or re-irradiation followed by chemotherapy. Mol Clin Oncol 10:49–57Google Scholar
  20. 20.
    Taal W, Segers-van Rijn JM, Kros JM et al (2012) Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol 108:195–200CrossRefGoogle Scholar
  21. 21.
    Roberts N, Wadajkar AS, Winkles JA et al (2016) Repurposing platinum-based chemotherapies for multimodal treatment of glioblastoma. Oncoimmunology 5:e1208876CrossRefGoogle Scholar
  22. 22.
    Ando M, Minami H, Ando Y et al (2000) Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 6:4733–4738Google Scholar
  23. 23.
    Murray LJ, Bridgewater CH, Levy D (2011) Carboplatin chemotherapy in patients with recurrent high-grade glioma. Clin Oncol 23:55–61CrossRefGoogle Scholar
  24. 24.
    Pitter KL, Tamagno I, Alikhanyan K et al (2016) Corticosteroids compromise survival in glioblastoma. Brain 139:1458–1471CrossRefGoogle Scholar
  25. 25.
    Wong ET, Lok E, Gautam S, Swanson KD (2015) Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 113:232–241CrossRefGoogle Scholar
  26. 26.
    Wong E, Swanson KD (2019) Dexamethasone-friend or foe for patients with glioblastoma? JAMA Neurol. 1:11. Google Scholar
  27. 27.
    Cenciarini M, Valentino M, Belia S et al (2019) Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies. Front Mol Neurosci 12:65CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Veronica Villani
    • 1
  • Andrea Pace
    • 1
  • Antonello Vidiri
    • 2
  • Antonio Tanzilli
    • 1
  • Francesca Sperati
    • 3
  • Irene Terrenato
    • 3
  • Carosi Mariantonia
    • 4
  • Beatrice Casini
    • 4
  • Giulio Metro
    • 6
  • Marta Maschio
    • 1
  • Koudriavtseva Tatiana
    • 1
  • Francesco Cognetti
    • 5
  • Alessandra Fabi
    • 5
    Email author
  1. 1.Neuro-Oncology UnitIRCCS - Regina Elena National Cancer InstituteRomeItaly
  2. 2.Service of NeuroradiologyIRCCS - Regina Elena National Cancer InstituteRomeItaly
  3. 3.Biostatistic UnitIRCCS - Regina Elena National Cancer InstituteRomeItaly
  4. 4.Division of NeuropathologyIRCCS - Regina Elena’ National Cancer InstituteRomeItaly
  5. 5.Division of Medical OncologyIRCCS - Regina Elena National Cancer InstituteRomeItaly
  6. 6.Ospedale Santa Maria Della Misericordia Azienda Ospedaliera Di PerugiaPerugiaItaly

Personalised recommendations